<?xml version="1.0" encoding="UTF-8"?>
<p id="Par23">Interesting suggestions for future treatments could be the development of type II transmembrane serine protease (TMPRSS2) inhibitors like camostat mesilate, approved in Japan for the treatment of pancreatic inflammation [
 <xref ref-type="bibr" rid="CR10">10</xref>]. This drug could act by blocking the entry of the virus inside lung cells and disabling the activation of the spike protein of SARS-CoV [
 <xref ref-type="bibr" rid="CR10">10</xref>, 
 <xref ref-type="bibr" rid="CR13">13</xref>, 
 <xref ref-type="bibr" rid="CR31">31</xref>]. To be fully effective, it need to be used in combination with an Abelson (Abl) kinase inhibitors (i.e. the anticancer imatinib) which inhibits fusion of the virions at the endosomal membrane [
 <xref ref-type="bibr" rid="CR10">10</xref>, 
 <xref ref-type="bibr" rid="CR13">13</xref>, 
 <xref ref-type="bibr" rid="CR31">31</xref>, 
 <xref ref-type="bibr" rid="CR32">32</xref>].
</p>
